About Genflow Biosciences
Genflow Biosciences is a company based in Charleroi (Belgium) founded in 2020 by Eric Leire. It operates as a HealthTech. Genflow Biosciences offers products and services including GF-1002. Genflow Biosciences operates in a competitive market with competitors including Orgenesis, Ori Biotech, MaSTherCell, Cognate Bioservices and Cell-Easy, among others.
- Headquarter Charleroi, Belgium
- Founders Eric Leire
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genflow Biosciences Plc
-
Annual Revenue
Not available
-
Net Profit
-$1.99 M (USD)2.55as on Dec 31, 2024
-
EBITDA
-$2.39 M (USD)-6.06as on Dec 31, 2024
-
Latest Funding Round
$1.31 M (USD), Grant
Oct 22, 2024
-
Investors
Wallonia
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Genflow Biosciences
Genflow Biosciences is a publicly listed company on the LSE with ticker symbol GENF in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Genflow Biosciences
Genflow Biosciences offers a comprehensive portfolio of products and services, including GF-1002.
A compound targeting aging through SIRT6 gene delivery.
People of Genflow Biosciences
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Genflow Biosciences
Investors in Genflow Biosciences
Genflow Biosciences has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Wallonia and Capital Plus Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Access to government programs and development services is facilitated.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Genflow Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genflow Biosciences
Investment portfolio details for Genflow Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Genflow Biosciences
Detailed financials for Genflow Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genflow Biosciences Comparisons
Peer comparison for Genflow Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genflow Biosciences
Genflow Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Orgenesis, Ori Biotech, MaSTherCell, Cognate Bioservices and Cell-Easy, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cell and gene therapies for multiple disorders are developed.
|
|
| Locked | Locked | Locked |
Software development services are provided for the biopharma sector.
|
|
| Locked | Locked | Locked |
Services for cell therapy development and manufacturing are provided.
|
|
| Locked | Locked | Locked |
Development and manufacturing services for cell-based therapies are provided.
|
|
| Locked | Locked | Locked |
Stem cell-based therapy services for research solutions are provided.
|
Detailed competitors of Genflow Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genflow Biosciences
Complete news archive for Genflow Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genflow Biosciences
Genflow Biosciences was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Genflow Biosciences is headquartered in Charleroi, Belgium. It is registered at Charleroi, Walloon Region, Belgium.
Eric Leire is the current CEO of Genflow Biosciences. They have also founded this company.
Genflow Biosciences is engaged in the research and development of novel therapeutic solutions aimed at slowing or halting the aging process in humans and dogs. Based in the UK, the company operates with RD facilities in Belgium and focuses on innovative gene therapies, such as the GF-1002 compound, which utilizes a centenarian variant of the SIRT6 gene. Their work targets the reduction of healthcare costs and addresses social challenges associated with aging populations through direct intervention in biological aging mechanisms.
Genflow Biosciences's top competitors include Ori Biotech, MaSTherCell and Orgenesis.
Genflow Biosciences offers GF-1002.
Yes, Genflow Biosciences is publicly traded on LSE under the ticker symbol GENF.
Genflow Biosciences has 2 investors. Key investors include Wallonia, and Capital Plus Partners.
The ticker symbol of Genflow Biosciences is GENF on LSE.